Coherus Oncology
CHRS
117 hedge funds and large institutions have $741M invested in Coherus Oncology in 2016 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 40 increasing their positions, 23 reducing their positions, and 8 closing their positions.
388% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
74% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 23
73% more capital invested
Capital invested by funds: $428M → $741M (+$313M)
36% more funds holding
Funds holding: 86 → 117 (+31)
84% less call options, than puts
Call options by funds: $644K | Put options by funds: $3.99M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.7M |
| 2 |
O
OrbiMed
New York
|
+$18.3M |
| 3 |
Millennium Management
New York
|
+$16.5M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$10.4M |
| 5 |
BM
Bridger Management
New York
|
+$9.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$16.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$15.2M |
| 3 |
VM
VHCP Management
New York
|
-$8.33M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$7.13M |
| 5 |
VMI
VHCP Management II
New York
|
-$3.54M |
CHRS Hedge Fund Activity: Q3 2016 in Review
117 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2016, worth a combined $741M — up 73% from $428M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new CHRS positions and 8 closed out — a net gain of 31 holders — while 40 added to existing stakes and 23 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $22.7M. The largest seller was Wellington Management Group, cutting an estimated $16.1M.
- 117 institutional investors held Coherus Oncology (CHRS) as of Q3 2016, up from 86 in Q2 2016.
- Funds reported $741M of Coherus Oncology stock for Q3 2016, up 73% quarter-over-quarter.
- 39 funds opened new Coherus Oncology positions in Q3 2016 and 8 closed out, a net change of +31 holders.
- The largest Coherus Oncology buyer in Q3 2016 was T. Rowe Price Associates, an estimated $22.7M added.
- The largest Coherus Oncology seller in Q3 2016 was Wellington Management Group, an estimated $16.1M sold.
Based on aggregated 13F filings for Q3 2016.